Attach up to 3 Basic Fighting Energy cards from your discard pile to your Benched Pokémon in any way you like.
During your next turn, this Pokémon can't use Mega Brave.
Mega Evolution entered circulation in 2025. It belongs to the Mega Evolution series.
The checklist contains 188 cards, placing it in a large expansion range. As of 2026, the set is 1 year old and still in a recent release window.
Within this set, Mega Lucario ex is card number 179 with a Special Illustration Rare designation.
In 2025, Mega Evolution introduced this print of Mega Lucario ex. Its card type is Pokémon.
The rarity label is Special Illustration Rare. Printed HP is 340.
Energy typing is Fighting. This card evolves from Riolu.
The card text reads: Mega Evolution ex Rule: When your Mega Evolution Pokémon ex is Knocked Out, your opponent takes 3 Prize cards. The printed attacks highlight "Aura Jab" and "Mega Brave".
Mega Lucario ex from Mega Evolution is currently trading around $155.01. Price action is stable over 7 days, moving only +0.4%.
Current pricing is broadly aligned with its 30-day average ($157.69). Its 90-day trading band runs between $147.55 and $196.36, producing a 31% range and moderate-volatility behavior.
Rarity classification for this copy is Special Illustration Rare.
Other Mega printings create a useful comparison set for Mega Lucario ex. Comparable entries in this snapshot: 5 cards, 3 distinct sets.
Observed alternatives run from $1.30 to $274.27 (20998% spread). The current card sits +164% versus the sampled alternative average of $58.70.
Notable alternatives include Mega Lucario ex #12 (Mega Evolution Black Star Promos) at $1.38, Mega Lucario ex #113 (Ascended Heroes) at $1.37, Mega Lucario ex #188 (Mega Evolution) at $274.27, and Mega Lucario ex #77 (Mega Evolution) at $1.30.
Market structure summary: Over the last 7 days, prices have remained stable at +0.4%, indicating a consolidation phase over sudden breakouts. The 90-day range spans $147.55 to $196.36 (31% spread), which indicates moderate-volatility behavior.
Relative to the 30-day baseline ($157.69), pricing is near equilibrium. Condition sensitivity is substantial: PSA 10 carries a +141% premium over raw value.
PSA 9 is currently around $158.67, while PSA 10 is $373.21.
